We also demonstrate in mouse models, that agonistic EphA2 targeting agents are very effective in suppressing cell migration and tumor metastases, hence anticipating the possible use of such agents in innovative anti-metastatic therapeutic modalities. Here, EPHA2 is linked to neoplasm.